# Aurelia Private Equity

> Aurelia Private Equity is a VC fund backing Biotechnology and Music. See 3 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Frankfurt, Germany
- Total investments: 3
- Last investment: Jan 2011
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/aurelia-private-equity-gmbh/
- Website: http://www.aurelia-pe.de
- Facebook: https://www.facebook.com/AureliaPrivateEquityGmbh/

Aurelia Private Equity is a VC fund in Frankfurt focused on Biotechnology and Music. Aurelia Private Equity is focused on investments in early-stage technology companies in Germany.Intelligent capital is the mainstay of the venture capital business. As a classic early-stage financer and startup consultant, they are interested in fast-growing, technology-oriented companies with great future potential. They see themselves as anentrepreneurial partner who, in addition to capital, also engages in strategic coaching, networking and commercial expertise. AURELIA PRIVATE EQUITY has a partnership-organized structure. Through the participation of all professionals in the decision-making process and in economic success, our actions are characterized by entrepreneurial thinking.

## Contacts

5 contacts available for Aurelia Private Equity. Shizune tracks 4 team members at Aurelia Private Equity. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/aurelia-private-equity?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 2 | 67% |
| Music | 1 | 33% |
| Medical | 1 | 33% |
| Messaging | 1 | 33% |
| Health Care | 1 | 33% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 67% |
| Series B | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Germany | 2 | 67% |
| Singapore | 1 | 33% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jurgen Leschke | Managing Partner | 0 | — |
| Jutta Kurz | Assistant | 0 | — |
| J. Wolfgang Posselt | Managing Partner | 0 | — |
| Sabine Weinert | Administration | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GILUPI | GILUPI GmbH, a Potsdam, Germany-based company that develops and produces medical devices for the in vivo isolation of rare cells out of the circulating blood. | $3.9M | Series C | Jan 13, 2011 |  |
| Club Cooee | Club Cooee is a 3D social network where millions of users from all over the world meet and connect in user-generated rooms. Users chat, party, DJ, dance, run music clubs, quiz, dress-up, design, sell their own creations and hang out with friends.Located in Kaiserslautern, Germany, Club Cooee is backed by venture investors Aurelia PrivateEquity, Generis Capital Partners, IPSA and ISB. |  | Series B | Oct 27, 2010 |  |
| MerLion Pharma | MerLion Pharmaceuticals.drug discovery and development company, engages in the research and development of natural products. It operates through two business units, MerLion Research and MerLion Development. The MerLion Research unit is a contract services business, which provides access to natural product collections by offering sample/extractsupply services, extract profiling and standardization, assay development, throughput screening, compound purification and structural identification, biocatalyst isolation, and strain improvement. The MerLion Development unit is progressing finafloxacin, a differentiated antibacterial candidate through phase II clinical trials, which is targeted initially for the eradication of Helicobacter pylori and treatment of urinary tract infections. It also provides portfolio of earlier-stage, preclinical antibacterial, and oncology programmes. The company serves pharmaceutical, industrial biotechnology, agro science, food and flavorings, cosmetics, and personal healthcare companies. MerLion Pharmaceuticals Pte. Ltd. was founded in 2002 and is based in Singapore, Singapore with clinical development operations in Berlin, Germany. | $7M | Series C | Oct 11, 2010 |  |

3 of 3 investments shown.

## Co-investors
- [Aravis Ventures](https://shizune.co/investors/profile/aravis-ventures) — VC Fund, 1 deal together
- [BC Brandenburg Capital](https://shizune.co/investors/profile/bc-brandenburg-capital) — VC Fund, 1 deal together
- [Brandenburg Kapital](https://shizune.co/investors/profile/bfb-brandenburg-kapital-gmbh) — VC Fund, 1 deal together
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund, 1 deal together
- [Generis Capital Partners](https://shizune.co/investors/profile/generis-capital-partners) — VC Fund, 1 deal together
- Viroad Biotechnology — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Aurelia Private Equity invest in?

Aurelia Private Equity invests primarily in Biotechnology, Music and Medical startups, most often at Series C and Series B stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Aurelia Private Equity?

Public channels for Aurelia Private Equity include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Aurelia Private Equity?

The team at Aurelia Private Equity includes Jurgen Leschke (Managing Partner), Jutta Kurz (Assistant) and J. Wolfgang Posselt (Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co